Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and fixed income markets across the globe. It targets attractive medium to long term returns by investing in leading long-only and alternative investment funds with proven managers and across multiple asset classes. The firm invests in separately managed account portfolios.

Syncona Limited

Syncona, is a leading FTSE 250 healthcare company focused on creating, building and scaling a portfolio of global leaders in life science.

Our vision is to build a sustainable, diverse portfolio of 20- 25 companies focused on delivering transformational treatments to patients in truly innovative areas of healthcare, through which we are seeking to deliver strong risk-adjusted returns for shareholders.

We take a long-term view, underpinned by a strategic capital base which enables us to maintain significant ownership positions in our companies and provides us with control and flexibility over the management of our portfolio. We believe we have the team, track record and skill-set to capture the superior returns available from commercialising exceptional science.

Nightstar Therapeutics

Orbit Biomedical

Blue Earth Diagnostics

Freeline

Gyroscope Therapeutics

Achilles Therapeutics

Autolus

Neogene Therapeutics

Syncona CEO, Chris Hollowood, and Executive Partner, John Tsai, MD, were both quoted in the latest ‘Scrip Asks…’ series on what does 2024 hold for biopharma in therapeutic area advances.

Chris comments on the significant acceleration and innovation that we’re seeing in science, and the translation of that science into new medicines. He also speaks on gene therapies, which have started to deliver transformational benefits for patients and even cures for previously uncurable diseases. Whilst John predicts that there will be a continued focus on exciting innovation for novel medicines targeting large disease populations of unmet need, such as in cardiovascular, metabolic and renal disease.

Read more here: https://lnkd.in/eNRMWRb8

#biotech #pharma #lifesciences

Syncona was pleased to recently welcome J. Jill Hopkins, MD, Chief Medical Officer and President Research & Development at Aura Biosciences, for a fireside chat, where she was interviewed by Chris Hollowood. 
 
Jill covered her background and experience in medicine, and her motivation for choosing to move into industry. She also provided unique insights on her varied experience across biotech and pharma, as well as her perspectives on balancing a family life with her career. She was incredibly generous in answering a range of questions from across the team who appreciated the opportunity to hear from a true leader in her field. 
 
#lifesciences #ophthalmology #biotech #pharma

Executive Partner John Tsai, MD discusses his return to the front line of innovation, working hands on with early-stage #biotech. 
 
John joined Syncona in May 2023 from Novartis AG where he was President, Global Drug Development and Chief Medical Officer. 

At Syncona John leverages his unique perspective to work closely with portfolio companies as they navigate the clinical pathway, taking executive roles at portfolio companies such as Forcefield Therapeutics where John leads the company as CEO.

Read more here: https://lnkd.in/evUsrgjz 

#lifesciences #drugdevelopment

Syncona Limited Board Chair, Melanie Gee, has been shortlisted for the Non-Executive Director Awards.
 
The FTSE All Share category recognises contribution to the organisation’s strategy and financial outcomes, and demonstration of high ethical standards and sound corporate governance.
 
See the full shortlist here: https://lnkd.in/eqRDWRV7
 
#lifesciences #FTSEAllShare #NEDAwards

We’re #hiring!

Want to work as part of a team that has a shared vision to unlock the potential from truly innovative science to transform patients’ lives?
 
Syncona is looking for a Financial Planning Analyst that will improve analysis and insight across the business and drive ongoing improvements to financial controls, systems and processes.
 
Find out more about here: https://lnkd.in/enVc3ghN
 
#lifesciences #talentacquisition #financialanalyst

John Tsai, MD, Executive Partner at Syncona, was featured in the latest edition of ‘Scrip Asks…’, speaking on trends in clinical trials.

There’s a positive outlook for patient recruitment in the future with John predicting the increased personalisation seen in clinical trials in oncology will expand to other therapeutic areas. He cites his belief that the shift will be amplified by predictive analytics and AI tools which will further accelerate the recruitment and conduct of clinical trials.

Read the full article here: https://lnkd.in/eB97zS8P

#lifesciences #biotech

Beacon Therapeutics presented 12-month data from its Phase II SKYLINE trial of its lead asset, AGTC-501, in XLRP at the Annual Macula Society Meeting, demonstrating encouraging efficacy and safety.
 
The presentation highlighted encouraging efficacy shown by improvements in retinal sensitivity, the primary endpoint for the trial, with a 63% response rate in the higher dose cohort. Beacon expects to announce longer term 24-month data from the trial in H2 CY2024.
 
Read the full announcement here: https://lnkd.in/d4Qfpq6d
 
#ophthalmology #blindness

Syncona portfolio company, Autolus Therapeutics today announced a Strategic Collaboration with BioNTech SE.
 
The Strategic Collaboration aims to advance both companies’ autologous CAR-T programmes towards commercialisation, pending regulatory authorisations. In connection with the collaboration, the companies entered into a license and option agreement and a securities purchase agreement, with BioNTech agreeing to purchase $200 million of Autolus’ American Depository Shares. In addition, BioNTech has made a cash payment of $50 million in return for access to a number of rights across Autolus’ pipeline.  

Autolus has also announced the pricing of its underwritten offering in the United States of 58,333,336 American Depositary Shares at a public offering price of $6.00 per ADS, for total gross proceeds of approximately $350 million.

Autolus is now well funded to deliver obe-cel’s path in relapsed/refractory adult acute lymphoblastic leukaemia and will be able to accelerate its oncology pipeline programmes to deliver its potentially transformational product to patients.

 Read the full announcements here: https://lnkd.in/d_uMTv_J

#lifesciences #biotech #celltherapy

Today Syncona published its third quarter update. 
 
Against a continuing challenging market backdrop for biotech we reported net assets of £1,251.0 million, equivalent to 188.2p per share, representing a NAV per share return of 5.4% in the quarter and 0.9% in the nine months to 31 December 2023. 
 
The Syncona team continues to take proactive and decisive action across the portfolio to maximise value. As part of this focus on creating fundamental value, Syncona is prioritising capital allocation across the portfolio to enable delivery of key inflection points that it believes have the potential to drive access to capital and NAV growth. 
 
Read the full announcement here: https://lnkd.in/eT9qDuzy
 
#lifesciences #biotech

Two Syncona portfolio companies, Autolus Therapeutics and Quell Therapeutics, have been featured in Labiotech.eu’s shortlist of UK #biotech companies to highlight.

Autolus is currently preparing for commercial launch having recently announced the acceptance of its Biologics License Application by the FDA for its lead programme in relapsed/refractory adult B-cell acute lymphoblastic #leukaemia. Quell is a Treg cell therapy company with a lead candidate in clinical development targeting the management of the body’s immune response to liver transplantation. 

Read the full article here: https://lnkd.in/e2paqqVx

#lifesciences #oncology #liverdisease

	Mar '14	Mar '15	Mar '16	Mar '17	Mar '18	Mar '19	Mar '20	Mar '21	Mar '22	Mar '23	Mar '24
asset turnover	0.03 -	0.11 271.86%	0.01 91.29%	0.09 826.78%	0.18 98.81%	0.31 71.40%	-0.11 134.63%	0.07 162.21%	0.03 62.68%	-0.02 174.79%	0.05 369.53%
cash conversion cycle						-6.13 -
cash per share	0.18 -	0.00 99.97%	0.00 77.37%	0.00 112.66%	0.00 555.21%	0.00 90.74%	0.00 81.35%	0.00 17.94%	0.00 1,866.12%	0.00 59.24%	0.00 135.44%
company equity multiplier	1.01 -	1.01 0.15%	1.01 0.08%	1.01 0.35%	1.01 0.75%	1.02 0.20%	1.02 0.78%	1.03 0.49%	1.02 1.10%	1.01 0.69%	1.01 0.11%
days of inventory outstanding
days of payables outstanding						13.03 -
days of sales outstanding	14.46 -	29.19 101.84%	367.00 1,157.41%	20.94 94.29%	8.84 57.79%	6.90 21.91%	-23.97 447.26%	42.06 275.42%	105.18 150.08%	-153.36 245.82%	51.95 133.87%
dividend yield	0.01 -	0.01 73.70%	0.01 2.30%	0.01 13.78%	0.01 1.87%	0.01 29.14%	0.01 34.13%
ebit per revenue	0.71 -	0.90 26.95%	-0.21 123.44%	0.93 541.47%	0.88 5.34%	0.88 0.53%	1.41 59.05%	0.59 58.32%	0.26 55.28%	2.34 790.93%	0.06 97.46%
ebt per ebit	1 -	1 0%	1 0%	1 0%	1 0%	1 0%	1 0%	1 0%	1 0%	1 0%	1 0%
effective tax rate
enterprise value multiple	27.23 -	9.32 65.76%	-504.89 5,514.72%	8.67 101.72%	7.11 17.99%	4.12 42.07%	-7.04 270.85%	31.74 550.86%	120.56 279.81%	-1.72 101.43%	208.21 12,184.87%
fixed asset turnover
free cash flow per share	0.02 -	0.01 20.40%	0.02 7.33%	0.02 1.24%	0.01 19.26%	0.00 96.35%	0.02 4,282.97%	-0.00 100.02%	0.00 8,809.82%	-0.00 1,134.43%	0.03 866.61%
gross profit margin	1 -	1 0%	1 0%	1 0%	1 0%	0.93 7.48%	1 8.09%	1 0%	1 0%	1 0%	1 0%
interest coverage
inventory turnover
long term debt to capitalization
net income per ebt	1 -	1 0%	1 0%	1 0%	1 0%	1 0%	1 0%	1 0%	1 0%	1 0%	1 0%
net profit margin	0.71 -	0.90 26.95%	-0.21 123.44%	0.93 541.47%	0.88 5.34%	0.88 0.53%	1.41 59.05%	0.59 58.32%	0.26 55.28%	2.34 790.93%	0.06 97.46%
operating cash flow per share	0.02 -	0.01 20.40%	0.02 7.33%	0.02 1.24%	0.01 19.26%	0.00 96.35%	0.02 4,282.97%	-0.00 100.02%	0.00 8,809.82%	-0.00 1,134.43%	0.03 866.61%
operating cycle						6.90 -
operating profit margin	0.71 -	0.90 26.95%	-0.21 123.44%	0.93 541.47%	0.88 5.34%	0.88 0.53%	1.41 59.05%	0.59 58.32%	0.26 55.28%	2.34 790.93%	0.06 97.46%
payables turnover						28.01 -
pretax profit margin	0.71 -	0.90 26.95%	-0.21 123.44%	0.93 541.47%	0.88 5.34%	0.88 0.53%	1.41 59.05%	0.59 58.32%	0.26 55.28%	2.34 790.93%	0.06 97.46%
price fair value	0.70 -	0.97 38.14%	1.07 10.57%	0.75 29.95%	1.17 55.60%	1.16 0.05%	1.10 5.17%	1.30 17.49%	0.81 37.30%	0.08 90.54%	0.64 727.78%
receivables turnover	25.24 -	12.51 50.46%	0.99 92.05%	17.43 1,652.25%	41.29 136.91%	52.87 28.06%	-15.22 128.80%	8.68 157.00%	3.47 60.01%	-2.38 168.58%	7.03 395.21%
return on assets	0.02 -	0.10 372.08%	-0.00 102.04%	0.09 4,191.42%	0.16 88.20%	0.28 72.30%	-0.15 155.08%	0.04 125.93%	0.01 83.31%	-0.04 766.30%	0.00 106.86%
return on capital employed	0.02 -	0.10 372.08%	-0.00 102.04%	0.09 4,218.96%	0.16 87.08%	0.28 72.31%	-0.15 155.27%	0.04 125.94%	0.01 83.31%	-0.04 766.85%	0.00 106.82%
return on equity	0.02 -	0.10 372.77%	-0.00 102.04%	0.09 4,177.16%	0.16 89.61%	0.28 72.65%	-0.16 155.51%	0.04 126.06%	0.01 83.50%	-0.04 761.71%	0.00 106.85%
total debt to capitalization

COM:SYNCONALTD

Syncona Ltd.

Last Close

99.20

25/11 09:20

Market Cap

7.63M

Beta: -

Volume Today

98.57K

Avg: -

Preview